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Abstract
The matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases. Their
primary function is degradation of proteins in the extracellular matrix. Currently, at least 19
members of this family are known to exist. Based on substrate specificity and domain
organization, the MMPs can be loosely divided into four main groups: the interstitial
collagenases, gelatinases, stromelysins and membrane-type MMPs. Recent data from model
systems suggest that MMPs are involved in breast cancer initiation, invasion and metastasis.
Consistent with their role in breast cancer progression, high levels of at least two MMPs
(MMP-2 and stromelysin-3) have been found to correlate with poor prognosis in patients
with breast cancer. Because MMPs are apparently involved in breast cancer initiation and
dissemination, inhibition of these proteinases may be of value both in preventing breast
cancer and in blocking metastasis of established tumours
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Introduction
The MMPs, which are also known as matrixins, are a family
of structurally and functionally related endoproteinases
that are involved in the degradation of the extracellular
matrix (ECM). Physiologically, these enzymes play a role in
normal tissue remodelling events such as embryonic
development, angiogenesis, ovulation, mammary gland
involution and wound healing. Abnormal expression
appears to contribute to various pathological processes
including rheumatoid arthritis and osteoarthritis, pulmonary
emphysema, and tumour growth, invasion and metastasis
(for review [1••]). Currently, at least 19 different MMPs are
known to exist in mammalian systems.
The main characteristics of these proteinases have pre-
viously been described in detail [1••,2••], and are there-
fore only briefly mentioned here. All MMPs possess
specific domains that are conserved between different
members. Catalytic activity depends on the presence of
zinc ions at the catalytic active site. Most MMPs are
synthesized and secreted in a zymogen form. Activation
is usually accompanied by loss of a 10-kDa amino-termi-
nal domain. Most cleave at least one component of the
ECM. Finally, proteolytic activity is inhibited by tissue
inhibitors known as tissue inhibitors of metallopro-
teinase (TIMPs).http://breast-cancer-research.com/content/2/4/252
Subgroups of matrix metalloproteinases
Based on in vitro substrate specificity and domain struc-
ture, the MMPs have traditionally been divided into four
main subgroups: the interstitial collagenases, gelatinases,
stromelysins and membrane MMPs [1••,2••]. The collage-
nases comprise interstitial collagenase (MMP-1), neutrophil
collagenase (MMP-8) and collagenase 3 (MMP-13). These
MMPs catalyze degradation of fibrillar forms of collagen (ie
types I, II and III). MMP-1 shows a preference for the type
III form, MMP-8 preferentially degrades type I collagen,
and MMP-13 has highest affinity for type II collagen [3].
The gelatinases, which are also known as type IV collage-
nases, degrade gelatin (denatured collagen), and types IV,
V, VII, IX and X collagen. Type IV collagen is particularly
abundant in basement membranes, which are the mem-
branes that separate organ parenchyma from the underly-
ing stroma. Degradation of type IV collagen by gelatinases
occurs within the triple helical regions. This subgroup has
two distinct members, known as gelatinase A (MMP-2) and
gelatinase B (MMP-9). Generally, these two gelatinases are
thought to have similar substrate specificity with respect to
ECM substrates, but may have different specificity toward
growth factor receptors [4]. An example of the latter is the
release of the soluble ectodomain of fibroblast growth
factor (FGF) receptor-1 by MMP-2, but not by MMP-9.
The third subgroup of MMPs are the stromelysins (ie
stromelysin-1 [MMP-3], stromelysin-2 [MMP-10],
stromelysin-3 [MMP-11] and matrilysin [MMP-7]). The
stromelysins have relatively broad substrate specificity,
catalyzing degradation of many different substrates in the
ECM [1••,2••]. The substrates include proteoglycans (core
protein), noncollagenous proteins such as laminin,
fibronectin and the nonhelical regions of collagen IV.
Stromelysin-3, on the other hand, has not yet been found
to degrade any matrix protein, but has been shown to
hydrolyze the serine proteinase inhibitor a1-proteinase
inhibitor [5]. It should be stated, however, that a carboxyl-
terminal truncated form of mouse stromelysin-3 has been
shown to exhibit weak stromelysin-like activities [6]. A
further difference between stromelysin-3 and the other
stromelysins is that stromelysin-3 is processed intracellu-
larly by furin [7]. Thus, stromelysin-3 can be secreted as a
potentially active protease. This intracellular activation dis-
tinguishes stromelysin-3 from most of the other MMPs,
which are secreted as latent proteases and activated in
the extracellular space. Because of its restricted substrate
specificity and intracellular activation, it could be argued
that stromelysin-3 represents the first member of a new
MMP subgroup rather than being the fourth member of the
stromelysin family.
The fourth subgroup consists of the membrane-type
MMPs, which possess a transmembrane domain [8]. Five
members of this group have been described, the best
characterized species being membrane-type 1 MMP. This
MMP has been shown to catalyze activation of progelati-
nase A [9], to degrade a variety of ECM substrates [9]
and to function as a fibrinolytic enzyme in the absence of
plasmin [10]. As with stromelysin-3, the membrane-type
MMPs posses a consensus domain that is recognized by
a furin-like enzyme.
The ADAMs (a disintegrin and metalloproteinase like) are a
group of molecules that are related to the MMPs. The
ADAMs share some or all of the following domains: a
signal peptide, a propeptide, a MMP domain, a disintegrin
domain, a cysteine-rich region, an epidermal growth factor-
like sequence, a transmembrane region and a cytoplasmic
tail (for review [11••]). Currently, 23 members of the ADAM
family are known to exist, and at least three of these (ie
ADAM-10, -12 and -17) have been shown to possess pro-
teinase activity [11••]. Unlike the MMPs, little work has
been done to address the role of ADAMs in cancer.
Inhibitors of matrix metalloproteinases
Four endogenous specific inhibitors of MMPs have been
described: TIMP-1, -2, -3 and -4 [2••,12•]. The TIMPs
inhibit protease activity by forming high-affinity 1:1 stoi-
chiometric, noncovalent complexes with the active MMPs.
In addition to binding to the active form, TIMP-1 can
complex with pro-MMP-9, whereas TIMP-2 binds to the
precursor form of MMP-2 [2••]. The complexes with the
precursor forms involve the carboxyl-terminal domains of
both the TIMPs and the MMPs. In contrast to the MMPs,
at least one of the ADAMs (tumour necrosis factor-a-con-
verting enzyme [TACE]) is not inhibited by TIMP-1, -2 or -4
[13]. TACE activity, however, is blocked by TIMP-3 [13].
Some TIMPs appear to act as multifunctional molecules.
Thus, in addition to inhibition of MMP activity, TIMP-1 and
TIMP-2 can stimulate cell proliferation, at least in vitro
[2••,12•]. Furthermore, although both TIMP-1 and TIMP-2
have been found to inhibit apoptosis [14,15], TIMP-3 was
shown to promote this process [16].
Role of matrix metalloproteinases in breast
cancer
Tumour initiation and growth
It is generally believed that the key genes involved in breast
carcinogensis are c-oncogenes such as c-erbB-2, c-myc,
ras, some members of the ets family, and tumour suppres-
sor genes such as p53 and Rb [17•]. Recent evidence,
however, suggests that certain MMPs may also play a role
in breast cancer initiation and growth. Indeed some of the
c-oncogenes may contribute to tumourigenesis by regulat-
ing the expression of MMPs. For example, transfection of
MCF-10A breast cancer cells with either c-erbB-2 or c-ras
resulted in increased expression of MMP-2 [18], whereas
transfection of MCF-7 cells with the ets gene, PEA-3, led
to increased production of MMP-9 [19].Breast Cancer Research    Vol 2 No 4 Duffy et al
Evidence that implicates MMPs in breast cancer genesis
and/or growth is as follows. Overexpression of
stromelysin-1 in transgenic mice gave rise to preneoplas-
tic and malignant mammary gland tumours [20,21]. Trans-
fection of MCF-7 cells with stromelysin-3 constructs
resulted in increased tumour take after subcutaneous
injection into nude mice [22]. In the latter situation, overex-
pression of stromelysin-3 did not appear to either modify
cell proliferation or confer an invasive phenotype on the
breast cells. Inactivation of the stromelysin-3 gene led to
decreased chemical-induced tumourigenesis in mice [23].
Transgenic mice expressing matrilysin under the control of
mouse mammary tumour virus (MMTV-long terminal repeat
promoter/enhancer) developed premalignant hyperplastic
nodules [24]. Mating MMTV–matrilysin mice with MMTV–
neu transgenic mice resulted in offspring that developed
mammary tumours substantially earlier than MMTV–neu
controls. Administration of batimastat (a synthetic inhibitor
of MMPs) reduced the rate of tumour formation in mice
injected with MDA-MB-435 breast cancer cells [25].
Finally, overexpression of TIMP-4 in the same cell line
reduced tumour growth [26].
Possible mechanisms by which MMPs contribute to cancer
initiation or to tumour cell growth include promotion of
angiogenesis, activation of stimulating growth factors or
their receptors, and inactivation of inhibiting growth factors.
Stimulation of angiogenesis
Angiogenesis is necessary for a tumour to grow to a size
greater than approximately 2mm in diameter. The process
begins with local degradation of the basement mem-
branes that surround capillaries, followed by invasion of
the surrounding stroma by the underlying endothelial cells
in the direction of the angiogenic signal. Endothelial cell
migration is accomplished by cell growth at the leading
edge of the migrating column. The endothelial cells then
organize themselves into three-dimensional structures to
form new capillary tubes (for review [27••]).
MMPs may promote angiogenesis by at least two differ-
ent mechanisms: by degrading barriers and thereby
allowing endothelial cell invasion; and by liberating
factors that promote or maintain the angiogenic pheno-
type [28•]. An example of the latter is the degradation of
the ECM protein laminin-5 by MMP-2, which results in
enhanced mammary epithelail cell growth [28•]. Similarly,
both MMP-1 and MMP-3 have been shown [28•] to
breakdown endothelial-derived perlecan, releasing basic
FGF, a potent endothelial mitogen.
It is important to point out that, although clear evidence
exists that MMPs potentiate angiogenesis, these pro-
teases also have the potential to inhibit this process. For
example, a number of MMPs, such as MMP-3, -7, -9 and
-12, can degrade plasminogen, generating the angiogene-
sis inhibitor angiostatin [28•]. Another potent inhibitor of
angiogenesis is endostatin, which is a breakdown product
of collagen XV111 [28•]. It is presently unknown whether
MMPs play a role in generating endostatin.
Activation of growth factors and their receptors
It was mentioned above that MMP-1 and MMP-3 can
release the endothelial cell mitogen basic FGF, which is
bound in the ECM. MMP activity, however, may also
release mitogens for epithelial cells. For example, a
member of the ADAM family, known as TACE, has been
shown to cause cell-shedding of transforming growth
factor-a, tumour necrosis factor-a and other growth
factors [29]. In a further study [30], MMP inhibitors were
shown to reduce cell proliferation in direct proportion to
their effect on transforming growth factor-a release. An
MMP-like protease also appears to be responsible for the
cleavage of the ectodomain of c-erbB-2 [31]. The release
of this amino-terminal sequence may lead to enhanced
signalling by the residual membrane-associated oncopro-
tein [31]. The increased signalling may in turn lead to
enhanced tumour cell proliferation. Also, as mentioned
above, MMP-2, but not MMP-9, has been shown [4] to
release the ectodomain of FGF receptor 1. Because the
hydrolyzed ectodomain retains its ability to bind FGF, it
has the potential to modulate the mitogenic and angio-
genic activities of FGF. Finally, stromelysin-3 has been
shown [23] to promote growth of MCF-7 cells by liberat-
ing ECM-associated growth factors.
Degradation of inhibitory growth factors
Although degradation of inhibiting growth factors by
MMPs could theoretically lead to increased cell prolifera-
tion, there is currently no evidence for this mechanism.
Matrix metalloproteinases and metastasis
The evidence that links MMPs with invasion and metasta-
sis is now extensive and has been widely reviewed [1••,
2••]. Consequently, the following discussion focuses only
on the role of these proteinases in the spread of breast
cancer.
Evidence that implicates MMPs in breast cancer dissemi-
nation is as follows. Batimistat reduced both lung colo-
nization and spontaneous metastasis of a highly malignant
rat mammary cancer [32]. In mouse mammary cancer cell
lines, inhibition of stromelysin-1 by antisense
oligodeoxynucleotides prevented invasion of an artificial
basement membrane [33]. The ratio of active to latent
form of MMP-2 increased with tumour progression in inva-
sive breast cancers [34]. Transfection of TIMP-4 into the
invasive human breast cancer cell line MDA-MB-435
reduced invasion in an in vitro model system [26]. Finally,
overexpression of TIMP-2 in MDA-231 cells reduced
osteolytic lesions after injection of these cells into nude
mice [35].Mechanisms by which matrix metalloproteinases promote
invasion and metastasis
It is generally assumed that the primary mechanism by
which MMPs promote cancer spread is by degradation of
the ECM, which consists of two main components: base-
ment membranes and interstitial connective tissue.
Although collagen IV is the main component of basement
membranes, other proteins such as laminin, proteogly-
cans, entactin and osteonectin are also present in this
structure. To establish metastatic growth, cancer cells
must pass through basement membranes at least three
times. Breast cancer cells initially cross these membranes
when an in situ carcinoma becomes an invasive lesion.
Later, malignant cells transverse these structures during
both entry into and exit from the blood stream.
The collagen IV component of basement membranes is
thought to be degraded mostly by MMP-2 and MMP-9.
These MMPs may therefore play a critical role in the con-
version of in situ breast cancers to invasive lesions. Early
work by Barsky et al [36] found that ‘type IV collagenase
immunoreactivity’ was present in all of 25 invasive breast
cancers, but not in any in situ malignancy.
In contrast to the acellular basement membrane, the inter-
stitial connective tissue is composed of cells distributed in
a meshwork of collagen fibres, glycoproteins, proteogly-
cans and hyaluronic acid. The main forms of collagen
found here are types I, II and III. During cancer dissemina-
tion, the interstitial connective tissue is believed to be
broken down mainly by the interstitial collagenases and
some of the stromelysins.
A frequent site of breast cancer metastasis is to bone, where
the presence of cancer cells upset the balance between
bone resorption and bone formation, resulting in net bone
loss. Thus, the main effect of breast cancer metastasis in
bone is degradation, which appears to be primarily mediated
by osteoclasts [37]. This osteoclast-induced bone resorption
is also catalyzed by MMPs [37], although the specific MMPs
that are involved have not yet been identified.
Matrix metalloproteinases as prognostic
markers in breast cancer
The early data that implicated MMPs in metastasis [38•]
were based on correlations between levels of specific MMPs
and metastatic potential in model systems. Over 10 years
ago, we originally proposed [39] that proteinases causally
involved in experimental metastasis might be markers of
metastatic potential or prognosis in human cancers.
Presently, high levels of two MMPs (ie MMP-2 and
stromelysin-3) have been found [2••,40] to correlate with
poor outcome in patients with breast cancer. Neither of
these MMPs has thus far been shown to be prognostic in
axillary node-negative breast cancer patients, however.
Paradoxically, high levels of both TIMP-1 and TIMP-2 have
also been shown [2••,41,42] to predict adverse outcome in
breast cancer patients. Similar results have also been found
with plasminogen activator inhibitor-1, an inhibitor of uroki-
nase-type plasminogen activator [43]. These findings
suggest that certain endogenous proteinase inhibitors, rather
than preventing metastasis, may potentiate the process.
Matrix metalloproteinases as targets for
breast cancer prevention and antimetastatic
therapies
The data from model systems, reviewed above, suggest
that MMPs are involved in most phases of carcinogenesis
from initiation to metastasis. Inhibition of these proteinases
might thus lead both to prevention of cancer development
and to inhibition of dissemination. Because of this poten-
tial, considerable research in recent years has focused on
different approaches to block the actions of MMPs.
Two main types of MMP inhibitor exist: the TIMPs and low-
molecular-weight synthetic inhibitors [2••,10]. Because of
their protein nature and multiplicity of actions, it is unlikely
that TIMPs will be widely used as anticancer molecules.
Because of this, most research in recent years has focused
on the synthetic inhibitors. Many of these are peptides and
are similar to the cleavage site in collagen [44]. Inhibition is
effected by a zinc-binding group that is adjacent to the P1¢
position. Some of the zinc-binding groups that are currently
being investigated in model systems include the hydroxya-
mates, carboxylates, amino carboxylates and sulphydryls
[44,45]. Some of these inhibitors (eg the hydroxyamates)
are presently undergoing clinical trials in patients with
advanced cancers [45,46]. We are unaware of any studies
so far in human breast cancer, however.
Although MMP inhibitors are currently being evaluated in
patients with metastatic cancers, there are still many unan-
swered questions concerning the use of these com-
pounds. Some of these are as follows.
Is it better to use a broad spectrum or specific matrix
metalloproteinase inhibitor? In order to answer this ques-
tion, it will be necessary to establish which are the MMPs
whose involvement in the different phases of cancer pro-
gression is critical.
If the action of MMP inhibitors is blocking of MMP activity
only, these compounds may not induce the type of tumour
shrinkage that is seen with the traditionally used cytotoxic
agents. Conventional approaches that are used to assess
tumour regression may thus not be possible. A novel
approach taken to address this issue has been to monitor
the rate of rise in levels of serum tumour markers [46]. The
use of these tests in phase 2 trials has shown a dose-
dependent decrease in rate of rise after treatment with the
MMP inhibitor Marimastat (British Biotech, Oxford, UK)
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[45]. Furthermore, this decreased rate of marker rise
appeared to correlate with extended patient survival [46].
Because MMPs have functional overlap with other pro-
teases (eg plasmin), it is unclear whether blockage of the
MMPs alone will prevent cancer initiation or progression.
Preliminary data from model systems [47] suggest that
arrest of invasion will require inhibition of plasmin as well
as of the MMPs.
Do MMPs inhibitors promote apoptosis? The primary sub-
strates of MMPs are generally thought to be the ECM
components. As mentioned above, however, some MMPs
also mediate cell shedding of membrane-bound growth
factors. Recently, two different synthetic MMP inhibitors
(BB-3103 and A-151011) were shown to induce apopto-
sis in Ewing’s sarcoma cell lines [48], apparently by inhibi-
tion of a MMP-like enzyme that releases membrane-bound
fas ligand. One of the endogenous inhibitors of MMPs,
TIMP-3, has also been shown [15] to cause apoptosis.
Both TIMP-1 and TIMP-2, on the other hand, have been
shown [14,15] to suppress apoptosis.Clearly further work
is necessary to clarify the role of MMP inhibitors in pro-
grammed cell death.
Conclusion
There is now strong evidence from model systems to
suggest that MMPs are involved in both tumour initiation
and progression. In these systems, administration of MMP
inhibitors can prevent cancer cell growth as well as inhibit
invasion and metastasis. Use of MMP inhibitors in humans
has so far been limited to patients with advanced disease.
Theoretically, it might be expected that the main anti-
cancer benefit of these compounds would be in the adju-
vant treatment setting (eg in combination with tamoxifen or
chemotherapy for breast cancer). Finally, with the recent
findings that MMPs are also involved in cancer initiation,
MMP inhibitors could also be considered for evaluation as
cancer chemopreventive molecules.
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